|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | TNF - α targeted therapeutic approaches in patients with hematologic malignancies 显示文摘 | Tsimberidou AM Giles FJ | 2002 | Expert Review of Anticancer Therapy2002，2，3： | 1 |
| 2 | PIK3CA Mutations Frequently Coexist with RAS and BRAF mutations in Patients with Advanced Cancers显示文摘 | Janku F Lee JJ Tsimberidou AM | 2011 | PLoS One2011，6，22： | 1 |
| 3 | PIK3CA mutations in patients with advanced cancers treated with PI3K/ AKT/mTOR axis inhibitors 显示文摘 | Janku F Tsimberidou AM Garrido-Laguna I | 2011 | Mol Cancer Ther2011，10，3： | 1 |
| 4 | Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia显示文摘 | Tsimberidou AM Kantarjian HM Wen Sijin | | 0，，06： | 1 |
| 5 | Clinical outcomes and prognostic factors in patients with Riehter syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation 显示文摘 | Tsimberidou AM O13rien S Khouri I | 2006 | J Clin Onco12006，24，15： | 1 |
| 6 | PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors 显示文摘 | Janku F Tsimberidou AM Garrido-Laguna I | 2011 | Mol Cancer Ther2011，10，3： | 1 |
| 7 | The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes显示文摘 | Tsimberidou AM Estey E Wen S | 2008 | Cancer2008，113，7： | 1 |
| 8 | Clinical outcomes and prognostic factors in patients with Richtegs synd,~me t,~ated with chemotherapy or chemoimnmnotherapy with or without stem-cell transplantation 显示文摘 | Tsimberidou AM O'Brien S Khouri 1 | 2006 | J Clin Onco12006，24，15： | 1 |
| 9 | Immunosuppression and infectious complications in patients with stage Ⅳ indolent lymphoma treated with a fludarabine, mitoxantrone, and dexaethasone regimen显示文摘 | Tsimberidou AM Younes A Romaguera J | 2005 | Cancer2005，104，2： | 1 |
| 10 | Per- sonalized medicine in a phase I clinical trials program: the MD anderson cancer center initiative显示文摘 | TSIMBERIDOU AM ISKANDER NG HONG DS | 2012 | Clin Cancer Res2012，18，22： | 1 |
| 11 | Cardiovascular toxicity profiles of vascular-disrupting agents 显示文摘 | Subbiah IM Lenihan D J Tsimberidou AM | 2011 | Oncologist2011，16，8： | 1 |
| 12 | Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage Ⅳ indolent lymphoma 显示文摘 | Tsimberidou AM Mclaughlin P Younes A | 2002 | Blood2002，100，： | 1 |
| 13 | Evaluation of the clinical relevance of body composition parameters in patients with Cancer metastatic to the liver treated with hepatic arterial infusion chemotherapy显示文摘 | Parsons HA Tsimberidou AM Pontikos M | 2012 | Nutr Cancer2012，64，： | 1 |
| 14 | Richter syndrome:biology,incidence,and therapeutic strategies显示文摘 | Tsimberidou AM Keating MJ | 2005 | Cancer2005，103，2： | 1 |
| 15 | Clinical outcomes and prognostic faetors in patients with Richter's syndrome treated with chemotherapy or ehemoimmunotherapy with or without stem-eell transplantation 显示文摘 | Tsimberidou AM OBrien S Khouri I | 2006 | J Clin Oneo12006，24，15： | 1 |
| 16 | Richter syndrome: biology, incidence, and therapeutic strategies 显示文摘 | Tsimberidou AM Keating MJ | 2005 | Cancer2005，103，2： | 1 |
| 17 | Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy显示文摘 | Tsimberidou AM Kantarjian HM Estey E | 2003 | Leukemia2003，17，6： | 1 |
| 18 | Evaluation of the clinical r-elevance of the expression and function of P-glycoprotein,multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia显示文摘 | Paterakis G Androutsos G | 2002 | Leuk Res2002，26，2： | 1 |
| 19 | A phase I study of fludarabine,cytarabine,and oxaliplatin therapy in patients with relapsed or refractory acute myeloid leukemia显示文摘 | Tsimberidou AM Keating MJ Jabbour EJ | 2014 | Clin Lymphoma Myeloma Leuk2014，14，： | 1 |
| 20 | Fractionated cydophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia显示文摘 | Tsimberidou AM Kantarjian HNI Cortes J | 2003 | Cancer2003，97，7： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员